“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A trial of everolimus with trastuzumab and vinorelbine for advanced HER2 positive breast cancer (BOLERO 3)
This trial looked at a drug called everolimus alongside trastuzumab (Herceptin) and chemotherapy for breast cancer that has spread to another part of the body. The trial was for women with breast cancer that has large amounts of the protein
Doctors can use a drug called trastuzumab (Herceptin) to treat HER2 positive
The aims of this trial were to find out
- If having everolimus alongside trastuzumab (Herceptin) and vinorelbine helps women with HER2 positive breast cancer that has spread to another part of the body
- More about the side effects
Summary of results
The trial team found that having everolimus alongside trastuzumab and vinorelbine helped women with HER2 positive secondary breast cancer.
569 women who had become resistant to trastuzumab (Herceptin) and who had already had treatment with
- 284 women had trastuzumab, vinorelbine and everolimus
- 285 women had trastuzumab, vinorelbine and a dummy drug (placebo)
The trial team looked at the average length of time women lived without signs of their cancer getting worse. They found this was
- 7 months in the group who had everolimus
- Just under 6 months in the group who had the dummy drug
More women in the everolimus group had problems with a sore mouth, tiredness (fatigue) and a drop in red and white blood cells causing an increased risk of infections and tiredness.
The trial team concluded that the combination of everolimus, trastuzumab and vinorelbine extended the length of time before the cancer started to grow again in this group of women but it caused more side effects.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)